Maya Guglin, MD
Cardiovascular Disease · New Brunswick, NJNPI 1144268871
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 78.8% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $11,646 and has fallen 82.1% since, to $2,090 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $168.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$23K
- Cvrx, Inc.$3K
- Abiomed$1K
- W. L. Gore & Associates, Inc.$600
- Novartis$189
- Novo Nordisk$171
- plus $984 from 19 others
Across 29 payments — averaging $3700.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$48K
- AstraZeneca$31K
- Boehringer Ingelheim$24K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
What the payments were for
- Consulting fees$16,27655%
- Speaking & faculty fees$6002%
- Travel & lodging$5,79520%
- Food & beverage$7,01524%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 89 | $23,400 |
| Cvrx, Inc. | 25 | $3,036 |
| Abiomed | 13 | $1,327 |
| W. L. Gore & Associates, Inc. | 1 | $600 |
| Novartis | 7 | $189 |
| Novo Nordisk | 3 | $171 |
| Edwards Lifesciences | 2 | $121 |
| Akcea Therapeutics, Inc. | 1 | $107 |
| Eurofins Viracor, LLC | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $93 |
| Merck | 5 | $90 |
| Atricure, Inc. | 3 | $84 |
| Pfizer | 4 | $65 |
| AstraZeneca | 2 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $49 |
| Bayer | 2 | $31 |
| Kestra Medical Technology Services, Inc. | 2 | $30 |
| Ancora Heart, Inc. | 1 | $28 |
| Endotronix, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$9,920
- HeartMate 3 Left Ventricular Dev$8,749
- Barostim Neo System$2,656
- CARDIOMEMS$1,521
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,089
- Impella$683
- Product in Development$600
- HeartMate Touch$144
- HeartMate 3 Left Ventricular Assist Device$142
- CentriMag$140
- MitraClip$131
- Mitra Clip system$114
- TEGSEDI$107
How this compares
$29,707 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 44 | $37,924 |
| JardianceEmpagliflozin | 21 | $32,521 |
| Sirolimus | 53 | $16,679 |
| FarxigaDapagliflozin Propanediol | 16 | $9,366 |
| Tacrolimus | 65 | $4,335 |
| Mycophenolate Mofetil | 46 | $3,240 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $1,321 |
| Torsemide | 59 | $1,004 |
| Amiodarone Hcl | 14 | $765 |
| Cephalexin | 15 | $371 |
| Metoprolol Succinate | 32 | $371 |
| FenofibrateFenofibrate Nanocrystallized | 19 | $348 |
| Omeprazole | 34 | $337 |
| Warfarin Sodium | 29 | $314 |
| Pantoprazole Sodium | 54 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $189 | $37,92444 claims |
| Boehringer IngelheimJardiance | $16 | $32,52121 claims |
| AstraZenecaFarxiga | $57 | $9,36616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in New Brunswick
- Ramzan ZakirNew Brunswick$342K
- John KostisNew Brunswick$225K
- Ashok ChaudharyNew Brunswick$144K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.